BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)

Bridge­Bio inks $250M PIPE two months af­ter PhI­II heart pill win, hints at more fi­nanc­ing

Bridge­Bio will gain about $250 mil­lion via a pri­vate in­vest­ment as the biotech nears an ap­proval sub­mis­sion for its heart pill, two months af­ter ini­tial­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.